Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
123 hedge funds and large institutions have $734M invested in Kezar Life Sciences in 2022 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 45 increasing their positions, 41 reducing their positions, and 11 closing their positions.
226% more call options, than puts
Call options by funds: $13.9M | Put options by funds: $4.25M
145% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 11
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
15% more funds holding
Funds holding: 107 → 123 (+16)
9% more capital invested
Capital invested by funds: $674M → $734M (+$60M)
10% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 41
3.69% less ownership
Funds ownership: 82.18% → 78.49% (-3.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$20M |
| 2 |
State Street
Boston,
Massachusetts
|
+$13M |
| 3 |
Holocene Advisors
New York
|
+$8.19M |
| 4 |
Millennium Management
New York
|
+$7.63M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$6.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$13M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4.33M |
| 3 |
SG Americas Securities
New York
|
-$3.87M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$3.59M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$3.43M |
KZR Hedge Fund Activity: Q1 2022 in Review
123 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q1 2022, worth a combined $734M — up 8.9% from $674M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new KZR positions and 11 closed out — a net gain of 16 holders — while 45 added to existing stakes and 41 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $20M. The largest seller was Morgan Stanley, cutting an estimated $13M.
- 123 institutional investors held Kezar Life Sciences (KZR) as of Q1 2022, up from 107 in Q4 2021.
- Funds reported $734M of Kezar Life Sciences stock for Q1 2022, up 8.9% quarter-over-quarter.
- 27 funds opened new Kezar Life Sciences positions in Q1 2022 and 11 closed out, a net change of +16 holders.
- The largest Kezar Life Sciences buyer in Q1 2022 was Victory Capital Management, an estimated $20M added.
- The largest Kezar Life Sciences seller in Q1 2022 was Morgan Stanley, an estimated $13M sold.
Based on aggregated 13F filings for Q1 2022.